Search Results - "Bui Nguyen, Binh"

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial by Demetri, George D, Prof, Reichardt, Peter, Prof, Kang, Yoon-Koo, Prof, Blay, Jean-Yves, Prof, Rutkowski, Piotr, MD, Gelderblom, Hans, MD, Hohenberger, Peter, Prof, Leahy, Michael, FRCP, von Mehren, Margaret, Prof, Joensuu, Heikki, Prof, Badalamenti, Giuseppe, MD, Blackstein, Martin, FRCP, Le Cesne, Axel, MD, Schöffski, Patrick, Prof, Maki, Robert G, Prof, Bauer, Sebastian, MD, Nguyen, Binh Bui, MD, Xu, Jianming, MD, Nishida, Toshirou, MD, Chung, John, MD, Kappeler, Christian, PhD, Kuss, Iris, MD, Laurent, Dirk, MD, Casali, Paolo G, MD

“…Summary Background Until now, only imatinib and sunitinib have proven clinical benefit in patients with gastrointestinal stromal tumours (GIST), but almost all…”
Get full text

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial by van der Graaf, Winette TA, Prof, Blay, Jean-Yves, Prof, Chawla, Sant P, MD, Kim, Dong-Wan, MD, Bui-Nguyen, Binh, MD, Casali, Paolo G, MD, Schöffski, Patrick, Prof, Aglietta, Massimo, MD, Staddon, Arthur P, MD, Beppu, Yasuo, MD, Le Cesne, Axel, MD, Gelderblom, Hans, Prof, Judson, Ian R, Prof, Araki, Nobuhito, MD, Ouali, Monia, MSc, Marreaud, Sandrine, MD, Hodge, Rachel, MSc, Dewji, Mohammed R, MSc, Coens, Corneel, MSc, Demetri, George D, MD, Fletcher, Christopher D, Prof, Dei Tos, Angelo Paolo, MD, Hohenberger, Peter, Prof

“…Summary Background Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in patients with advanced non-adipocytic soft-tissue…”
Get full text

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2 -amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study by Ray-Coquard, Isabelle, Dr, Blay, Jean-Yves, Prof, Italiano, Antoine, MD, Le Cesne, Axel, MD, Penel, Nicolas, MD, Zhi, Jianguo, PhD, Heil, Florian, PhD, Rueger, Ruediger, MD, Graves, Bradford, PhD, Ding, Meichun, PhD, Geho, David, MD, Middleton, Steven A, PhD, Vassilev, Lyubomir T, PhD, Nichols, Gwen L, MD, Bui, Binh Nguyen, MD

“…Summary Background We report a proof-of-mechanism study of RG7112, a small-molecule MDM2 antagonist, in patients with chemotherapy-naive primary or relapsed…”
Get full text

Dedifferentiated liposarcomas with divergent myosarcomatous differentiation developed in the internal trunk : A study of 27 cases and comparison to conventional dedifferentiated liposarcomas and leiomyosarcomas by MATTHIEU BUI NGUYEN BINH, GUILLOU, Louis, HOSTEIN, Isabelle, CHATEAU, Marie Christine, COLLIN, Francoise, AURIAS, Alain, BUI NGUYEN BINH, STOECKLE, Eberhard, COINDRE, Jean-Michel

“…Dedifferentiated liposarcoma (DLPS) is one of the most frequent sarcomas of the retroperitoneum and represents most undifferentiated sarcomas of the internal…”
Get full text

Prognostic factors in retroperitoneal sarcoma. A multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group by STOECKLE, Eberhard, COINDRE, Jean-Michel, BONVALOT, Sylvie, KANTOR, Guy, TERRIER, Philippe, BONICHON, Francoise, BINH NGUYEN BUI

“…Surgery is the main prognostic factor in retroperitoneal sarcoma. However, despite progress, surgery alone is rarely curative, and analysis of the causes of…”
Get full text

Retroperitoneal liposarcomas: Follow‐up analysis of dedifferentiation after clinicopathologic reexamination of 86 liposarcomas and malignant fibrous histiocytomas by Fabre‐Guillevin, Elizabeth, Coindre, Jean‐Michel, Somerhausen, Nicolas de Saint Aubain, Bonichon, Francoise, Stoeckle, Eberhard, Bui, Nguyen Binh

“…BACKGROUND Dedifferentiated liposarcoma (DDL) juxtapose components of well‐differentiated liposarcoma (WDL) and nonlipogenic sarcoma. Malignant fibrous…”
Get full text

Randomized Trial Comparing Bleomycin/Etoposide/Cisplatin With Alternating Cisplatin/Cyclophosphamide/Doxorubicin and Vinblastine/Bleomycin Regimens of Chemotherapy for Patients With Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP by CULINE, Stéphane, KRAMAR, Andrew, DELVA, Rémy, FARGEOT, Pierre, FIZAZI, Karim, BOUZY, Jeannine, DROZ, Jean-Pierre, THEODORE, Christine, GEOFFROIS, Lionel, CHEVREAU, Christine, BIRON, Pierre, BUI NGUYEN, Binh, HERON, Jean-Francois, KERBRAT, Pierre, CATY, Armelle

“…Two chemotherapy regimens for intermediate- and poor-risk metastatic nonseminomatous germ cell tumors were compared for efficacy and toxicity. From February…”
Get full text

A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases by Stoeckle, E, Coindre, J.M, Longy, M, Bui Nguyen Binh, M, Kantor, G, Kind, M, Tunon de Lara, C, Avril, A, Bonichon, F, Nguyen Bui, B

“…Abstract Background The management of desmoid tumours, previously based on strategies employed for sarcomas, should be reassessed, given the morbidity of…”
Get full text

High-dose pre-operative helical tomotherapy (54 Gy) for retroperitoneal liposarcoma by Sargos, Paul, Dejean, Catherine, de Figueiredo, Bénédicte Henriques, Brouste, Véronique, Nguyen Bui, Binh, Italiano, Antoine, Stoeckle, Eberhard, Kantor, Guy

“…To evaluate the feasibility of pre-operative radiotherapy (54 Gy) with Helical Tomotherapy (HT) followed by surgery. Ten patients with non-metastatic…”
Get full text

Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group by Le Cesne, Axel, Ray-Coquard, Isabelle, Duffaud, Florence, Chevreau, Christine, Penel, Nicolas, Bui Nguyen, Binh, Piperno-Neumann, Sophie, Delcambre, Corinne, Rios, Maria, Chaigneau, Loic, Le Maignan, Christine, Guillemet, Cecile, Bertucci, François, Bompas, Emmanuelle, Linassier, Claude, Olivier, Thimotée, Kurtz, Jean-Emmanuel, Even, Caroline, Cousin, Philippe, Yves Blay, Jean

“…Abstract Aim The French Sarcoma Group performed this retrospective analysis of the ‘RetrospectYon’ database with data of patients with recurrent advanced soft…”
Get full text

Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas by Blay, Jean-Yves, Leahy, Michael G, Nguyen, Binh Bui, Patel, Shreyaskumar R, Hohenberger, Peter, Santoro, Armando, Staddon, Arthur P, Penel, Nicolas, Piperno-Neumann, Sophie, Hendifar, Andrew, Lardelli, Pilar, Nieto, Antonio, Alfaro, Vicente, Chawla, Sant P

“…Abstract Aim This randomised phase III trial evaluated first-line trabectedin versus doxorubicin-based chemotherapy (DXCT) in patients with advanced/metastatic…”
Get full text

Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy by DEMETRI, George D, CHAWLA, Sant P, REICHARDT, Peter, BOMPAS, Emmanuelle, ALCINDOR, Thierry, RUSHING, Daniel, YANG SONG, LEE, Ruey-Min, EBBINGHAUS, Scot, EID, Joseph E, LOEWY, John W, HALUSKA, Frank G, RAY-COQUARD, Isabelle, DODION, Pierre F, BLAY, Jean-Yves, LE CESNE, Axel, STADDON, Arthur P, MILHEM, Mohammed M, PENEL, Nicolas, RIEDEL, Richard F, BUI-NGUYEN, Binh, CRANMER, Lee D

“…Aberrant mammalian target of rapamycin (mTOR) signaling is common in sarcomas and other malignancies. Drug resistance and toxicities often limit benefits of…”
Get full text

Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study by PENEL, Nicolas, BINH NGUYEN BUI, ISAMBERT, Nicolas, PEYRADE, Frédéric, CHEVREAU, Christine, BOMPAS, Emmanuelle, BRAIN, Etienne G. C, BLAY, Jean-Yves, BAY, Jacques-Olivier, CUPISSOL, Didier, RAY-COQUARD, Isabelle, PIPERNO-NEUMANN, Sophie, KERBRAT, Pierre, FOURNIER, Charles, TAIEB, Sophie, JIMENEZ, Marta

“…The objective of this phase II trial was to assess the efficacy and toxicity of weekly paclitaxel for patients with metastatic or unresectable angiosarcoma…”
Get full text

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial by Le Cesne, Axel, Dr, Ray-Coquard, Isabelle, MD, Bui, Binh Nguyen, MD, Adenis, Antoine, MD, Rios, Maria, MD, Bertucci, François, MD, Duffaud, Florence, MD, Chevreau, Christine, MD, Cupissol, Didier, MD, Cioffi, Angela, MD, Emile, Jean-François, MD, Chabaud, Sylvie, MsC, Pérol, David, MD, Blay, Jean-Yves, MD

“…Summary Background The effect of imatinib discontinuation on progression-free survival and overall survival in long-lasting responders with advanced…”
Get full text

Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST) by Le Cesne, Axel, Blay, Jean-Yves, Bui, Binh Nguyen, Bouché, Olivier, Adenis, Antoine, Domont, Julien, Cioffi, Angela, Ray-Coquard, Isabelle, Lassau, Nathalie, Bonvalot, Sylvie, Moussy, Alain, Kinet, Jean-Pierre, Hermine, Olivier

“…Abstract Background Masitinib is a tyrosine kinase inhibitor with greater in vitro activity and selectivity for the wild-type c-Kit receptor and its…”
Get full text

Phenotype and genotype features of Vietnamese children with pachyonychia congenita by Chu, Ha Thi, Dinh Duong, Tung Anh, Le, Doanh Huu, Le, Thieu Van, Nguyen, Binh Bui, Dang, Chuc Van, Vu, Quang Van

“…Pachyonychia congenita (PC) is a group of autosomal dominant disorders caused by mutations in one of five keratin genes (KRT6A, KRT6B, KRT6C, KRT16, or KRT17)…”
Get full text

Design and Realization of Polymeric Waveguide/Microring Structures for Telecommunication Domain by La, Thuy Linh, Bui, Binh Nguyen, Nguyen, Thi Thanh Ngan, Pham, Thi Lien, Tran, Quoc Tien, Tong, Quang Cong, Mikulich, Aliaksandr, Nguyen, Thanh Phuong, Nguyen, Thi Thu Thuy, Lai, Ngoc Diep

“…Polymer-based micro-optical components are very important for applications in optical communication. In this study, we theoretically investigated the coupling…”
Get full text

MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone by Dujardin, Fanny, Binh, Matthieu Bui Nguyen, Bouvier, Corinne, Gomez-Brouchet, Anne, Larousserie, Frédérique, Muret, Anne de, Louis-Brennetot, Caroline, Aurias, Alain, Coindre, Jean-Michel, Guillou, Louis, Pedeutour, Florence, Duval, Hélène, Collin, Christine, de Pinieux, Gonzague

“…Low-grade osteosarcoma is a rare malignancy that may be subdivided into two main subgroups on the basis of location in relation to the bone cortex, that is,…”
Get full text

Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors by Benjamin, Robert S., Schöffski, Patrick, Hartmann, Jörg Thomas, Van Oosterom, Allan, Bui, Binh Nguyen, Duyster, Justus, Schuetze, Scott, Blay, Jean-Yves, Reichardt, Peter, Rosen, Lee S., Skubitz, Keith, McCoy, Sheryl, Sun, Yu-Nien, Stepan, Daniel E., Baker, Laurence

“…Purpose This multicenter phase 2 study assessed the tolerability and efficacy of motesanib, an oral inhibitor of Kit, platelet-derived growth factor receptor…”
Get full text

Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: An ECSG/EORTC study by Ravaud, Alain, Cerny, Thomas, Terret, Catherine, Wanders, Jantien, Bui, Binh Nguyen, Hess, Dagmar, Droz, Jean-Pierre, Fumoleau, Pierre, Twelves, Chris

“…CHS 828 is a new guanidino-containing drug. The aim of this study was to determine the maximum tolerated dose (MTD), the recommended dose and the toxicity of…”
Get full text